CDNA vs JNJ: fair value comparison
CareDx, Inc. and Johnson & Johnson · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CDNA currently sits closer to the top of our discount ranking. CDNA carries the stronger quality grade.
| CDNA | JNJ | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $47.85 | $268.04 |
| 12-month range | $13.85–$47.85 | $178.06–$256.35 |
| Sector rank | #107 of 113 Healthcare | #109 of 113 Healthcare |
| Quality grade | A | F |
| Leverage | Low | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CDNA fair value analysis · JNJ fair value analysis